PMID- 31638330
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 96
IP  - 3
DP  - 2020 Sep 1
TI  - Identification of patients at higher risk for myocardial injury following 
      elective coronary artery intervention.
PG  - 578-585
LID - 10.1002/ccd.28549 [doi]
AB  - OBJECTIVES: To evaluate myocardial injury and infarction (MI) following elective 
      percutaneous coronary intervention (PCI). BACKGROUND: The substantially higher 
      analytical power of high-sensitivity troponin (hsTn) assays allows detection of 
      minor cardiac troponin (cTn) levels, which may be useful in monitoring myocardial 
      injury and guiding therapies. METHODS: Serial hsTnT measurements were conducted 
      in patients undergoing elective PCI and were related to the extent of coronary 
      artery disease (CAD) as reflected by the SYNTAX score risk categories and 
      American College of Cardiology/American Heart Association classification of 
      coronary lesions. Myocardial injury and MI were diagnosed according to the second 
      and third versions of universal MI definition. RESULTS: The study population 
      consisted of 530 patients, who were grouped into low (41.3%), intermediate 
      (35.4%), and high (23.3%) SYNTAX risk categories. The treated coronary lesions 
      were classified into A 7.8%, B1 24.1%, B2 21.1%, C1 24.6%, and C2 22.4%. 
      Postprocedural hsTnT increases correlated significantly with the complexity of 
      treated coronary lesions (p < .05) and CAD magnitude (p < .05). Rates of MI type 
      4a according to the second and third MI definition criteria were 98 (27.5%) and 
      15 (4.2%) cases in patients with normal baseline hsTnT values (N = 357, 67.4%), 
      as well as 137 (79.2%) and 27 (15.6%) cases in those with elevated baseline hsTnT 
      values (N = 173, 32.6%), respectively. CONCLUSIONS: After elective PCI, cTn 
      releases correlate significantly with lesion complexity and CAD extent. Use of 
      hsTnT assay enables precise monitoring of PCI-related myocardial injury and may 
      identify patients at higher risk for ischemic events, who may benefit from potent 
      platelet inhibition, which needs to be investigated in randomized trials.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Abu Sharar, Haitham
AU  - Abu Sharar H
AUID- ORCID: 0000-0002-8917-1126
AD  - Department of Cardiology, Angiology and Pneumology, Heidelberg University 
      Hospital, Heidelberg, Germany.
FAU - Helfert, Stefanie
AU  - Helfert S
AD  - Department of Cardiology, Angiology and Pneumology, Heidelberg University 
      Hospital, Heidelberg, Germany.
FAU - Vafaie, Mehrshad
AU  - Vafaie M
AD  - Department of Cardiology, Angiology and Pneumology, Heidelberg University 
      Hospital, Heidelberg, Germany.
FAU - Pleger, Sven T
AU  - Pleger ST
AD  - Department of Cardiology, Angiology and Pneumology, Heidelberg University 
      Hospital, Heidelberg, Germany.
FAU - Chorianopoulos, Emmanuel
AU  - Chorianopoulos E
AD  - Department of Cardiology, Angiology and Pneumology, Heidelberg University 
      Hospital, Heidelberg, Germany.
FAU - Bekeredjian, Raffi
AU  - Bekeredjian R
AD  - Department of Cardiology, Angiology and Pneumology, Heidelberg University 
      Hospital, Heidelberg, Germany.
FAU - Katus, Hugo A
AU  - Katus HA
AD  - Department of Cardiology, Angiology and Pneumology, Heidelberg University 
      Hospital, Heidelberg, Germany.
FAU - Giannitsis, Evangelos
AU  - Giannitsis E
AD  - Department of Cardiology, Angiology and Pneumology, Heidelberg University 
      Hospital, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20191022
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Biomarkers)
RN  - 0 (Troponin T)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Coronary Artery Disease/diagnostic imaging/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/*etiology
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Troponin T/blood
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - coronary artery disease
OT  - high sensitivity troponin assay
OT  - percutaneous coronary intervention
OT  - periprocedural myocardial injury
EDAT- 2019/10/23 06:00
MHDA- 2021/04/07 06:00
CRDT- 2019/10/23 06:00
PHST- 2019/02/25 00:00 [received]
PHST- 2019/09/30 00:00 [revised]
PHST- 2019/10/05 00:00 [accepted]
PHST- 2019/10/23 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2019/10/23 06:00 [entrez]
AID - 10.1002/ccd.28549 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2020 Sep 1;96(3):578-585. doi: 10.1002/ccd.28549. 
      Epub 2019 Oct 22.